{"organizations": [], "uuid": "0c1c3ce6e2825394c34ed9341a01bf426e76e5c7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/07/pr-newswire-pd-rx-declares-dividend.html", "country": "US", "domain_rank": 767, "title": "PD-Rx Declares Dividend", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.999, "site_type": "news", "published": "2018-05-07T15:00:00.000+03:00", "replies_count": 0, "uuid": "0c1c3ce6e2825394c34ed9341a01bf426e76e5c7"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/07/pr-newswire-pd-rx-declares-dividend.html", "ord_in_thread": 0, "title": "PD-Rx Declares Dividend", "locations": [], "entities": {"persons": [], "locations": [{"name": "oklahoma city", "sentiment": "none"}], "organizations": [{"name": "the board of directors of pd-rx pharmaceuticals, inc.", "sentiment": "neutral"}, {"name": "fda", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "OKLAHOMA CITY, May 7, 2018 /PRNewswire/ -- The Board of Directors of PD-Rx Pharmaceuticals, Inc., a publicly held corporation, (Symbol: PDRX) today announced that it has declared a one time dividend of $.66 per share payable on May 9, 2018 to shareholders of record at the close of business April 30, 2018. This dividend represents a 9.8% projected annual yield utilizing the April 25, 2018 closing market price of $6.75.\nABOUT THE COMPANY:\nPD-Rx offers pharmaceutical and management strategies to the healthcare industry. Our management strategies focus on new products, solid business partners, and the specialized segment of the pharmaceutical industry. As a licensed FDA manufacturer and packager, PD-Rx offers a full spectrum of medications and specialized services. Our goal is to develop a matrix of cost containment tools and products that we can merge into any healthcare network to enhance patient care and improve managed care organizations bottom line. We provide proprietary products and prepackaged medications that are viewed by patient, insurance payers and healthcare providers as a progressive and responsive practice.\nThis press release contains \"forward-looking\" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks and uncertainties or other factors, which may cause actual results, performance or achievements expressed or implied by such forward-looking statements to vary from those forecast or implied in this release. Factors that might cause such a difference include, without limitation, decline in demand for the company's products or services, and the effect of general economic conditions and factors affecting the industry.\nFor Further Information, Contact:\nJack L. McCall, EVP & COO\nPh. 405-942-3040 / jlm@pdrx.com\nView original content: http://www.prnewswire.com/news-releases/pd-rx-declares-dividend-300637669.html\nSOURCE PD-Rx Pharmaceuticals, Inc.", "external_links": ["http://www.prnewswire.com/news-releases/pd-rx-declares-dividend-300637669.html"], "published": "2018-05-07T15:00:00.000+03:00", "crawled": "2018-05-07T17:42:36.000+03:00", "highlightTitle": ""}